Evaluation of a radiomic approach based on hyperspectral retinal imaging to predict the cerebral amyloid status for the diagnosis of Alzheimer’s disease


The proposed project aims at validating and further developing a novel technology to predict the presence of significant amyloid (Aβ) deposition in the brain from a simple, non-invasive hyperspectral retina scan with Optina Diagnostics’ Metabolic Hyperspectral Retinal Camera (MHRC) in combination with an artificial intelligence algorithm. Accumulation of Aβ plaques in the brain is a key hallmark of Alzheimer’s disease (AD), but current methods to evaluate its presence in vivo (Aβ positron emission tomography imaging and quantification of Aβ proteins in the cerebrospinal fluid obtained) are not practically implementable as screening methods due to cost, availability and/or invasiveness nature. A simpler and cheaper method is urgently needed to help in the recruitment of asymptomatic, amyloid positive, subjects to test new disease modifying therapies for AD, and eventually to help clinicians confirm a diagnosis of AD in a subject presenting with cognitive impairment.